Literature DB >> 11574540

Multiple forms of mouse vascular endothelial growth factor-D are generated by RNA splicing and proteolysis.

M E Baldwin1, S Roufail, M M Halford, K Alitalo, S A Stacker, M G Achen.   

Abstract

The secreted glycoprotein vascular endothelial growth factor-D (VEGF-D) is angiogenic, lymphangiogenic, and promotes metastatic spread of tumor cells via lymphatic vessels. VEGF-D consists of a receptor-binding domain (VEGF homology domain) and N- and C-terminal propeptides. Proteolytic processing produces numerous forms of human VEGF-D, including fully processed derivatives (containing only the VEGF homology domain), partially processed, and unprocessed derivatives. Proteolysis is essential to generate human VEGF-D that binds the angiogenic receptor VEGF receptor-2 (VEGFR-2) and the lymphangiogenic receptor VEGFR-3 with high affinity. Here, we report that alternative use of an RNA splice donor site in exon 6 of the mouse VEGF-D gene produces two different protein isoforms, VEGF-D(358) and VEGF-D(326), with distinct C termini. The two isoforms were both expressed in all adult mouse tissues and embryonic stages of development analyzed. Both isoforms are proteolytically processed in a similar fashion to human VEGF-D to generate a range of secreted derivatives and bind and cross-link VEGFR-3 with similar potency. The isoforms are differently glycosylated when expressed in vitro. This study demonstrates that RNA splicing, protein glycosylation, and proteolysis are mechanisms for generating structural diversity of mouse VEGF-D.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11574540     DOI: 10.1074/jbc.M106188200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  22 in total

1.  Neoadjuvant Locoregional Therapy and Recurrent Hepatocellular Carcinoma after Liver Transplantation.

Authors:  Min Xu; Mb Majella Doyle; Babak Banan; Neeta Vachharajani; Xuanchuan Wang; Nael Saad; Kathryn Fowler; Elizabeth M Brunt; Yiing Lin; William C Chapman
Journal:  J Am Coll Surg       Date:  2017-04-09       Impact factor: 6.113

Review 2.  Gene and protein therapies utilizing VEGF for ALS.

Authors:  Orion P Keifer; Deirdre M O'Connor; Nicholas M Boulis
Journal:  Pharmacol Ther       Date:  2013-10-29       Impact factor: 12.310

3.  Nuclear localization of vascular endothelial growth factor-D and regulation of c-Myc-dependent transcripts in human lung fibroblasts.

Authors:  Souheil El-Chemaly; Gustavo Pacheco-Rodriguez; Daniela Malide; Victor Meza-Carmen; Jiro Kato; Ye Cui; Philip I Padilla; Arun Samidurai; Bernadette R Gochuico; Joel Moss
Journal:  Am J Respir Cell Mol Biol       Date:  2014-07       Impact factor: 6.914

Review 4.  Lymphangiogenesis and lymphatic vessel remodelling in cancer.

Authors:  Steven A Stacker; Steven P Williams; Tara Karnezis; Ramin Shayan; Stephen B Fox; Marc G Achen
Journal:  Nat Rev Cancer       Date:  2014-03       Impact factor: 60.716

5.  Pharmacological targeting of VEGFR signaling with axitinib inhibits Tsc2-null lesion growth in the mouse model of lymphangioleiomyomatosis.

Authors:  Elena N Atochina-Vasserman; Elena Abramova; Melane L James; Ryan Rue; Amy Y Liu; Nathan Tessema Ersumo; Chang-Jiang Guo; Andrew J Gow; Vera P Krymskaya
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2015-10-02       Impact factor: 5.464

6.  Vascular endothelial growth factor D is dispensable for development of the lymphatic system.

Authors:  Megan E Baldwin; Michael M Halford; Sally Roufail; Richard A Williams; Margaret L Hibbs; Dianne Grail; Hajime Kubo; Steven A Stacker; Marc G Achen
Journal:  Mol Cell Biol       Date:  2005-03       Impact factor: 4.272

Review 7.  The yin and yang of VEGF and PEDF: multifaceted neurotrophic factors and their potential in the treatment of Parkinson's Disease.

Authors:  Torsten Falk; Robert T Gonzalez; Scott J Sherman
Journal:  Int J Mol Sci       Date:  2010-08-05       Impact factor: 5.923

8.  Anti-angiogenesis effect of the novel anti-inflammatory and pro-resolving lipid mediators.

Authors:  Yiping Jin; Makoto Arita; Qiang Zhang; Daniel R Saban; Sunil K Chauhan; Nan Chiang; Charles N Serhan; Reza Dana
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-04-30       Impact factor: 4.799

9.  The propeptides of VEGF-D determine heparin binding, receptor heterodimerization, and effects on tumor biology.

Authors:  Nicole C Harris; Natalia Davydova; Sally Roufail; Sophie Paquet-Fifield; Karri Paavonen; Tara Karnezis; You-Fang Zhang; Teruhiko Sato; Julie Rothacker; Edouard C Nice; Steven A Stacker; Marc G Achen
Journal:  J Biol Chem       Date:  2013-02-12       Impact factor: 5.157

10.  A Simple Bioassay for the Evaluation of Vascular Endothelial Growth Factors.

Authors:  Steven A Stacker; Michael M Halford; Sally Roufail; Carol Caesar; Marc G Achen
Journal:  J Vis Exp       Date:  2016-03-15       Impact factor: 1.355

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.